Molecular Formula | C29H56N10O7 |
Molar Mass | 656.82 |
Density | 1.34±0.1 g/cm3(Predicted) |
Appearance | solid |
pKa | 12.04±0.10(Predicted) |
Storage Condition | -20°C |
In vitro study | SLIGRL-NH2 is an agonist of PAR-2 and MrgprC11. SLIGRL-NH2 causes an L-NAME-inhibited relaxation. Based on SLIGRL-NH 2 causing a concentration-dependent relaxation with an EC 50 of 10 µM in endothelium-free preparations in the presence of perivascular adipose tissue (PVAT) , 20 µM is used as a suitable ‘test’ concentration of peptide in subsequent experiments designed to evaluate the effects of potential inhibitors of ADRF release/action. In the endothelium-free aorta preparations, SLIGRL-NH2 causes a concentration-dependent relaxation in preparations only in the presence of PVAT [+PVAT, -ENDO (endothelium)]. |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |